Investigational drug · Phase 3
SHR-A1811
Also called: Trastuzumab Rezetecan
Not approved by FDA. In 27 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
27
27 still active
All registered trials
109
Any phase or sponsor naming "SHR-A1811"
First trial start
2022
Aug 4, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SHR-A1811", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Colorectal Cancer
- Recurrent or Metastatic Cervical Cancer
- Ovarian Cancer
- PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer
- Early-stage or Locally Advanced HER2-positive Breast Cancer
- Breast Cancer
- HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
- HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
- HER2-expressing Advanced Solid Tumors
- Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma
Approved drugs for the same conditions: Breast cancer · Colorectal cancer · Ovarian cancer · Stomach and esophageal cancer · Cervical cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "SHR-A1811" as an intervention, largest first.
- A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant TherapyPivotal-lookingActive, not recruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06126640 · 1,615 participants · Start Nov 20, 2023 · Primary completion Apr 2030
Drug: SHR-A1811; Trastuzumab Emtansine · For: HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Sites: Shanghai, China; Tianjin, China
- A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast CancerPivotal-lookingRecruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT07679360 · 1,000 participants (planned) · Start Sep 2, 2026 · Primary completion Dec 2030
Drug: Trastuzumab Rezetecan for Injection; Adebrelimab Injection and 2 more · For: Triple Negative Breast Cancer
Sites: Beijing, China
- A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast CancerPivotal-lookingActive, not recruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06057610 · 868 participants · Start Nov 1, 2023 · Primary completion Jul 15, 2026
Drug: SHR-A1811 Injection; SHR-A1811 Injection ; Pertuzumab Injection and 1 more · For: HER2-PositiveRecurrent or Metastatic Breast Cancer
Sites: Nanjing, China
- A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast CancerPivotal-lookingActive, not recruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT07196774 · 740 participants · Start Oct 23, 2025 · Primary completion Dec 2027
Drug: SHR-A1811 for Injection; Docetaxel injection and 3 more · For: Early-stage or Locally Advanced HER2-positive Breast Cancer
Sites: Shenyang, China; Shanghai, China
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT05582499 · 716 participants (planned) · Start Nov 1, 2022 · Primary completion Dec 31, 2027
Drug: Dalpiciclib; Pyrotinib and 30 more · For: Breast Neoplasm; Breast Cancer; Breast Tumors and 7 more
Sites: Shanghai, China
- SNF Platform Study of HR+/ HER2-advanced Breast CancerPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT05594095 · 620 participants (planned) · Start Dec 30, 2022 · Primary completion Dec 1, 2025
Drug: PIK3CA inhibitor; AKT inhibitor and 17 more · For: Breast Neoplasm; Breast Cancer; Hormone Receptor Positive Tumor and 2 more
Sites: Shanghai, China
- A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction AdenocarcinomaPivotal-lookingRecruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT07118527 · 600 participants (planned) · Start Aug 18, 2025 · Primary completion Oct 2030
Drug: SHR-A1811 + Adebrelimab Injection + Capecitabine Tablets or Fluorouracil Injection; Trastuzumab + Pembrolizumab + CAPOX( Capecitabine Tablets + Oxaliplatin) or FP (Fluorouracil Injection+Cisplatin) · For: Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma
Sites: Shenyang, China; Shanghai, China
- SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical TrialPivotal-lookingActive, not recruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT05814354 · 551 participants · Start Jun 30, 2023 · Primary completion Mar 20, 2026
Drug: SHR-A1811; Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel · For: Breast Cancer
Sites: Beijing, China
- A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung CancerPivotal-lookingNot yet recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT07896005 · 436 participants (planned) · Start Dec 2026 · Primary completion Feb 2031
Drug: SHR-A1811 Injection; Adebrelimab Injection and 4 more · For: Non Small Cell Lung Cancer
Sites: Shanghai, China; Hangzhou, China
- A Phase Ib/II Study of SHR-A1811 Injection in Breast CancerPivotal-lookingStatus unknown
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT05353361 · 402 participants (planned) · Start May 23, 2022 · Primary completion Dec 31, 2025
Drug: SHR-A1811:Pyrotinib; SHR-A1811;Pertuzumab and 2 more · For: Breast Cancer
Sites: Nanjing, China
Newest research
PubMed records naming it or its code names, newest first.
- Innovative therapies for HER2-altered non-small cell lung cancer: A narrative review.
Arrieta O, Caballé-Pérez E, Cabrera-Miranda L, et al. · Crit Rev Oncol Hematol 2026
- Trastuzumab rezetecan (SHR-A1811) for the treatment of HER2-positive advanced colorectal cancer: a report of two cases.
Chen D, Zheng Y · J Gastrointest Oncol 2026
- Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: The HORIZON-Breast06 Randomized Clinical Trial.
Fan Y, Liu Y, Wang Y, et al. · JAMA 2026
- Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: Research Summary.
· JAMA 2026
- Trastuzumab Rezetecan in EBBR2-Low Metastatic Breast Cancer: One More ADC or a New Opportunity?
Mosele MF, André F · JAMA 2026
- Erratum: Biomarker-Stratified Phase II Trial of Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma Across Cohorts With High and Low Human Epidermal Growth Factor Receptor 2 Expression.
Chen GL, Guo Y, Liu X, et al. · J Clin Oncol 2026
Also in development for Advanced Colorectal Cancer
- JAB-21822Glecirasib Citrate, KRAS G12C inhibitorPhase 310 trials
Allist Pharmaceuticals, Inc. · Non-small Cell Lung Cancer, KRAS P.G12C, Solid Tumor
- B1962Phase 22 trials
Tasly Biopharmaceuticals Co., Ltd. · Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Cervical Cancers
- RBS2418Phase 22 trials
Riboscience, LLC. · Metastatic Colorectal Cancer, Advanced Colorectal Cancer, Advanced Unresectable Hepatocellular Carcinoma
- VEGF antibodyPhase 22 trials
Lepu Biopharma Co., Ltd. · Hepatocellular Carcinoma, Advanced Colorectal Cancer
- MRG007Phase 21 trial
Lepu Biopharma Co., Ltd. · Advanced Colorectal Cancer
- TL938Phase 21 trial
Teligene US · Colorectal Cancer Metastatic, Advanced Colorectal Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.